Neuro Oncol. 2015 Apr;17(4):596-603. doi: 10.1093/neuonc/nou235. Epub 2014 Oct 14.

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Weiss B1, Widemann BC1, Wolters P1, Dombi E1, Vinks A1, Cantor A1, Perentesis J1, Schorry E1, Ullrich N1, Gutmann DH1, Tonsgard J1, Viskochil D1, Korf B1, Packer RJ1, Fisher MJ1.


Ther Drug Monit. 2016 Jan 21. [Epub ahead of print]

Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum.

Scott JR1, Courter JD, Saldaña SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AA.


Ther Drug Monit. 2015 Jun;37(3):395-9. doi: 10.1097/FTD.0000000000000130.

Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.

Emoto C1, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA.


Neuro Oncol.
 2015 Apr;17(4):596-603. doi: 10.1093/neuonc/nou235. Epub 2014 Oct 14.

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Weiss B1, Widemann BC1, Wolters P1, Dombi E1, Vinks A1, Cantor A1, Perentesis J1, Schorry E1, Ullrich N1, Gutmann DH1, Tonsgard J1, Viskochil D1, Korf B1, Packer RJ1, Fisher MJ1.

Neurology. 2016 Dec 13;87(24):2575-2584. Epub 2016 Nov 9.

Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.

Payne JM1, Barton B1, Ullrich NJ1, Cantor A1, Hearps SJ1, Cutter G1, Rosser T1, Walsh KS1, Gioia GA1, Wolters PL1, Tonsgard J1, Schorry E1, Viskochil D1, Klesse L1, Fisher M1, Gutmann DH1, Silva AJ1, Hunter SJ1, Rey-Casserly C1, Cantor NL1, Byars AW1, Stavinoha PL1, Ackerson JD1, Armstrong CL1, Isenberg J1, O'Neil SH1, Packer RJ1, Korf B1, Acosta MT1, North KN2; NF Clinical Trials Consortium.